Could antiretrovirals be treating EBV in MS? A case report

Author(s)
Drosu, Natalia; Edelman, Elazer R; Housman, David E
Thumbnail
Download1-s2.0-S2211034818300828-main.pdf (375.3Kb)
PUBLISHER_CC
Terms of use
Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/
Metadata
Show full item record
Abstract
We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, suggesting future directions for clinical investigation. Keywords: Multiple sclerosis, Epstein-Barr virus
Date issued
2018-05
URI
http://hdl.handle.net/1721.1/116814
Department
Institute for Medical Engineering and Science; Harvard University--MIT Division of Health Sciences and Technology; Massachusetts Institute of Technology. Department of Biology
Journal
Multiple Sclerosis and Related Disorders
Citation
Drosu, Natalia C., Elazer R. Edelman, and David E. Houseman. “Could Antiretrovirals Be Treating EBV in MS? A Case Report.” Multiple Sclerosis and Related Disorders, vol. 22, May 2018, pp. 19–21. © 2018 The Authors
Version: Final published version
ISSN
2211-0348
Collections